Market Dynamics

Increase in inpatients in hospital related to brain metastases and rising awareness among consumer related to availability of advanced treatment are major factors expected to drive the growth of global brain metastasis therapeutic market. Brain metastases occur when cancer cells spread from their original site to the brain. As the metastatic brain tumors grow, they create pressure on and change the function of surrounding brain tissue. According to American Association of Neurological Surgeons, approximately 200,000 new cases of brain metastases are diagnosed in the U.S. each year. Consumers spending on healthcare is increasing, with the rise in awareness among patients related to advanced medical treatment is resulting in government focus towards providing advanced care to patients. According to Information Technology & Innovation Foundation the direct and indirect annual costs of brain conditions amount to approximately 8.8 percent of GDP, or US$ 1.5 trillion. Major players are focused on R&D activities, they are investing high in drug development, conducting clinical trials with the focus to deliver novel treatments this is expected to augment the growth of brain metastasis therapeutic market.

In 2020, the U.S. Food and Drug Administration approved Seattle Genetics, Inc. for the “Tukysa”. Tukysa is for treatment of adult patients with advanced forms of HER2-positive breast cancer that can’t be removed with surgery, or has spread to other parts of the body, including the brain, and who have received one or more prior treatments.

In 2021, Taiho Pharmaceutical Co., Ltd. a global pharmaceutical company partnered with The University of Texas MD Anderson Cancer Center. The partnership is focused on development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.

Increasing homecare setting approach among consumers due to easy availability of advanced infrastructure is expected to support the brain metastasis therapeutic market growth. According to Centers for Medicare & Medicaid Services (CMS) the U.S. home health spending hit US$102.2 Bn in 2018. Major player’s inclination towards enhancing the business in developing countries in order to increase the customer base is expected to augment the market growth. Factors such as high cost associated to drug development and stringent government regulations related to product approval are expected to hamper the growth of global brain metastasis therapeutic market. In addition, lack of funding for R&D activities is expected to challenge the growth of target market. However, increasing investment by major players for novel drug development and rise in government spending on strengthening the R&D capabilities are factors expected to create new opportunities for players operating in the global brain metastasis therapeutic market over the forecast period. In addition, increasing partnership between regional and international players is expected to support the revenue transaction of the target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global brain metastasis therapeutic market due to high patient pool suffering from brain disorder. According to NCBI, brain metastases are the most common type of intracranial tumor. In the United States, an estimated 98,000 to 170,000 cases occur each year. Presence of large number of players operating in the country and availability of favorable reimbursement policies is expected to support the regional market growth.

Competitive Landscape      

The global brain metastasis therapeutic market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Brain Metastasis Therapeutic Market Segment Analysis, 2019

The global brain metastasis therapeutic market is segmented into treatment and end user. The treatment segment is divided into corticosteroids, anticonvulsants, targeted therapy, chemotherapy, and radiation therapy. The end use segment is bifurcated into cancer research centers, cancer hospitals, clinics, and others. Among end use the cancer hospitals segment is expected to account for major revenue share in the global brain metastasis therapeutic market. The players profiled in the report are F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Eli Lilly & Company, Merck & Co., Inc., Bayer AG, AngioChem Inc., Novartis AG, Pfizer Inc., , AstraZeneca, and  Sanofi

Market Segmentation

Market By Treatment

Corticosteroids
Anticonvulsants
Targeted therapy
Chemotherapy
Radiation therapy

Market By End Use

Cancer research centers
Cancer hospitals
Clinics
Others

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa